{"nctId":"NCT00491530","briefTitle":"A Year 2, Safety Extension Study of the Combination of ABT-335 and Statin Therapy for Subjects With Mixed Dyslipidemia","startDateStruct":{"date":"2007-06"},"conditions":["Mixed Dyslipidemia"],"count":310,"armGroups":[{"label":"ABT-335 + rosuvastatin calcium","type":"EXPERIMENTAL","interventionNames":["Drug: ABT-335","Drug: rosuvastatin calcium"]},{"label":"ABT-335 + simvastatin","type":"EXPERIMENTAL","interventionNames":["Drug: ABT-335","Drug: simvastatin"]},{"label":"ABT-335 + atorvastatin calcium","type":"EXPERIMENTAL","interventionNames":["Drug: ABT-335","Drug: atorvastatin calcium"]}],"interventions":[{"name":"ABT-335","otherNames":["fenofibric acid"]},{"name":"rosuvastatin calcium","otherNames":["Crestor"]},{"name":"simvastatin","otherNames":["Zocor"]},{"name":"atorvastatin calcium","otherNames":["Lipitor"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Adult male and female subjects who voluntarily sign the informed consent.\n* Subject has successfully completed the treatment phase of the preceding open-label year 1 study.\n\nExclusion Criteria:\n\n* Subject is using or will use investigational medications, except as approved by Abbott.\n* Subject has prematurely discontinued his/her combination therapy administered in the preceding open-label year 1 study.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Subjects Reporting Adverse Events During Combination Therapy in the Preceding Double-Blind Studies or in the Preceding Open-Label Year 1 Study or in This Open-Label Year 2 Study","description":"All serious and non-serious adverse events are reported from the time of combination study drug initiation until 30 days after discontinuation of study drug. Adverse events are unfavorable changes in health that occur in subjects during a clinical trial or within a specified period following a trial. Serious adverse events are those that result in death, require inpatient hospitalization or the prolongation of hospitalization, result in congenital anomaly/birth defect, or significant disability/incapacity or are life-threatening.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"94.8","spread":null},{"groupId":"OG001","value":"90.0","spread":null},{"groupId":"OG002","value":"97.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Median Percent Change in Triglycerides From Baseline to Week 104 of This Open-Label Year 2 Study","description":"\\[(Week 104 triglycerides minus baseline triglycerides)/baseline triglycerides\\] X 100. Baseline is the last value prior to the first dose of combination therapy.","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-36.9","spread":"34.91"},{"groupId":"OG001","value":"-29.6","spread":"36.61"},{"groupId":"OG002","value":"-38.7","spread":"32.31"}]}]}]},{"type":"SECONDARY","title":"Mean Percent Change in High-Density Lipoprotein Cholesterol (HDL-C) From Baseline to Week 104 of This Open-Label Year 2 Study","description":"\\[(Week 104 HDL-C minus baseline HDL-C)/baseline HDL-C\\] X 100. Baseline is the last value prior to the first dose of combination therapy.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.7","spread":"22.15"},{"groupId":"OG001","value":"11.2","spread":"22.53"},{"groupId":"OG002","value":"5.2","spread":"17.53"}]}]}]},{"type":"SECONDARY","title":"Mean Percent Change in Direct Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Week 104 of This Open-Label Year 2 Study","description":"\\[(Week 104 LDL-C minus baseline LDL-C)/baseline LDL-C\\] X 100. Baseline is the last value prior to the first dose of combination therapy.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-19.2","spread":"30.87"},{"groupId":"OG001","value":"-20.2","spread":"22.56"},{"groupId":"OG002","value":"-20.5","spread":"30.04"}]}]}]},{"type":"SECONDARY","title":"Mean Percent Change in Non-High-Density Lipoprotein Cholesterol (Non-HDL-C) From Baseline to Week 104 of This Open-Label Year 2 Study","description":"\\[(Week 104 Non-HDL-C minus baseline Non-HDL-C)/baseline Non-HDL-C\\] X 100. Baseline is the last value prior to the first dose of combination therapy.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-26.9","spread":"26.12"},{"groupId":"OG001","value":"-23.8","spread":"21.99"},{"groupId":"OG002","value":"-25.1","spread":"27.83"}]}]}]},{"type":"SECONDARY","title":"Mean Percent Change in Very Low-Density Lipoprotein Cholesterol (VLDL-C) From Baseline to Week 104 of This Open-Label Year 2 Study","description":"\\[(Week 104 VLDL-C minus baseline VLDL-C)/baseline VLDL-C\\] X 100. Baseline is the last value prior to the first dose of combination therapy.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-33.7","spread":"42.50"},{"groupId":"OG001","value":"-18.7","spread":"58.37"},{"groupId":"OG002","value":"-26.6","spread":"65.88"}]}]}]},{"type":"SECONDARY","title":"Mean Percent Change in Total Cholesterol (Total-C) From Baseline to Week 104 of This Open-Label Year 2 Study","description":"\\[(Week 104 Total-C minus baseline Total-C)/baseline Total-C\\] X 100. Baseline is the last value prior to the first dose of combination therapy.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-20.1","spread":"21.41"},{"groupId":"OG001","value":"-17.9","spread":"18.54"},{"groupId":"OG002","value":"-20.4","spread":"21.57"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":26,"n":174},"commonTop":["Upper respiratory tract infection","Headache","Back pain","Bronchitis","Nasopharyngitis"]}}}